KDM1A and neoplasm: Our data suggest that the combination of LSD1 inhibitor (SP2509) and PRMT5 inhibitor (EPZ015666) synergistically lead to a strong reduction of vimentin expression, induction of E-cadherin expression and decreased invasion of breast cancer cells in vitro, and also efficiently inhibit tumor growth and lung metastases of breast cancer in vivo.